Clinical study of capecitabine combined with radiotherapy in treatment of gastrointestinal tumor

Objective To evaluate the clinical efficacy and side effects of radiotherapy based on capecitabine on gastrointestinal tumor. Methods The clinical data of 40 patients with gastrointestinal tumor receiving radiation therapy from July 2011 to June 2015 were retrospectively analyzed, they were randomly divided into study group and control group according to double-blind, with 20 cases in each group. Both groups were given conventional radiation therapy, the study group received service capecitabine treatment based on this. The clinical efficacy of the two groups were evaluated and the 1-year, 3-year survival rate, incidence of toxicity were recorded. Results The efficiency and disease control rate were 55.0% and 85.0% in study group, which were higher than those in the control group (35.0% and 65.0%, P 0.05). Conclusions For patients with gastrointestinal tumor, on the basis of conventional radiotherapy in combination with capecitabine can improve the 3-year survival rate, prolong time to disease progression, but has little effect on the recent survival rate. Compared with radiotherapy alone, effectiveness and adverse reactions had no significant difference. In clinical recommendations, capecitabine combined with radiotherapy can be actively tried to improve long-term survival rate. Key words: Capecitabine; Radiotherapy; Gastrointestinal tumor; Survival rate; Adverse reaction